Lightning Biotherapeutics

Early-stage company co-founded by David Scadden and David Mooney, founders of Harvard Stem Cell Institute and Wyss Institute, respectively, is focused on novel modalities for immune reconstitution. The company is developing 2 complementary platforms for immune function restoration which are positioned to address unmet needs in acute thymic injury such as in post HSCT (Hematopoietic stem-cell transplantation) and in diseases of age-related immune decline.